Avantor (NYSE:AVTR – Get Free Report) issued its earnings results on Wednesday. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.01, FiscalAI reports. The business had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Avantor had a net margin of 5.08% and a return on equity of 9.79%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.22 earnings per share.
Here are the key takeaways from Avantor’s conference call:
- Avantor returned to organic revenue growth in Q3, with revenue up 5.2% organically to $1.698 billion. VWR grew 5.8%, while Bioscience & Medtech Products returned to growth at 3.6%, supported by improved execution and stronger demand.
- Management raised its 2026 outlook, now expecting organic revenue growth of 0.75%–1.25%, adjusted EPS of $0.81–$0.83, and free cash flow of $525–$550 million. The company expects adjusted net leverage to fall below 3.0x by year-end, compared with 3.1x at the end of Q3.
- The company cited continued momentum from its Revival program, including improved manufacturing throughput, supply-chain execution, customer service, e-commerce, and AI-enabled commercial tools. BMP also reported positive book-to-bill trends and strong performance in Process Chemicals and NuSil.
- Profitability remains pressured by product and customer mix, inflation, and targeted growth investments, particularly in VWR. Management said 2026 pricing of roughly 1%–2% has not fully offset inflation, while Europe remains a weak market and BMP faces approximately 400 basis points of discrete comparison headwinds in Q4.
Avantor Trading Down 4.0%
NYSE AVTR traded down $0.68 during mid-day trading on Friday, reaching $16.00. 4,005,298 shares of the stock were exchanged, compared to its average volume of 10,193,281. The stock has a market capitalization of $10.83 billion, a PE ratio of 31.97, a PEG ratio of 9.43 and a beta of 0.94. The business’s fifty day simple moving average is $15.46 and its 200 day simple moving average is $11.22. Avantor has a 1-year low of $7.26 and a 1-year high of $17.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.18 and a current ratio of 1.89.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on AVTR. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $17.00 target price on shares of Avantor in a research report on Thursday. Royal Bank Of Canada increased their price target on shares of Avantor from $14.00 to $17.00 and gave the company a “sector perform” rating in a research note on Wednesday. Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Jefferies Financial Group upgraded shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 29th. Finally, Robert W. Baird upped their target price on shares of Avantor from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Avantor has a consensus rating of “Hold” and an average price target of $14.77.
View Our Latest Analysis on Avantor
About Avantor
Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.
Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.
Recommended Stories
- Five stocks we like better than Avantor
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
